Literature DB >> 12504812

Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins.

J van der Velden1, Z Papp, R Zaremba, N M Boontje, J W de Jong, V J Owen, P B J Burton, P Goldmann, K Jaquet, G J M Stienen.   

Abstract

OBJECTIVE: The alterations in contractile proteins underlying enhanced Ca(2+)-sensitivity of the contractile apparatus in end-stage failing human myocardium are still not resolved. In the present study an attempt was made to reveal to what extent protein alterations contribute to the increased Ca(2+)-responsiveness in human heart failure.
METHODS: Isometric force and its Ca(2+)-sensitivity were studied in single left ventricular myocytes from non-failing donor (n=6) and end-stage failing (n=10) hearts. To elucidate which protein alterations contribute to the increased Ca(2+)-responsiveness isoform composition and phosphorylation status of contractile proteins were analysed by one- and two-dimensional gel electrophoresis and Western immunoblotting.
RESULTS: Maximal tension did not differ between myocytes obtained from donor and failing hearts, while Ca(2+)-sensitivity of the contractile apparatus (pCa(50)) was significantly higher in failing myocardium (deltapCa(50)=0.17). Protein analysis indicated that neither re-expression of atrial light chain 1 and fetal troponin T (TnT) nor degradation of myosin light chains and troponin I (TnI) are responsible for the observed increase in Ca(2+)-responsiveness. An inverse correlation was found between pCa(50) and percentage of phosphorylated myosin light chain 2 (MLC-2), while phosphorylation of MLC-1 and TnT did not differ between donor and failing hearts. Incubation of myocytes with protein kinase A decreased Ca(2+)-sensitivity to a larger extent in failing (deltapCa(50)=0.20) than in donor (deltapCa(50)=0.03) myocytes, abolishing the difference in Ca(2+)-responsiveness. An increased percentage of dephosphorylated TnI was found in failing hearts, which significantly correlated with the enhanced Ca(2+)-responsiveness.
CONCLUSIONS: The increased Ca(2+)-responsiveness of the contractile apparatus in end-stage failing human hearts cannot be explained by a shift in contractile protein isoforms, but results from the complex interplay between changes in the phosphorylation status of MLC-2 and TnI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504812     DOI: 10.1016/s0008-6363(02)00606-5

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  144 in total

1.  Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies.

Authors:  Nathan J Palpant; Fikru B Bedada; Brandon Peacock; Bruce R Blazar; Joseph M Metzger; Jakub Tolar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-12       Impact factor: 4.733

2.  Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia.

Authors:  Tilmann Schober; Sabine Huke; Raghav Venkataraman; Oleksiy Gryshchenko; Dmytro Kryshtal; Hyun Seok Hwang; Franz J Baudenbacher; Björn C Knollmann
Journal:  Circ Res       Date:  2012-05-29       Impact factor: 17.367

3.  Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes.

Authors:  Lili Wang; Kyungsoo Kim; Shan Parikh; Adrian Gabriel Cadar; Kevin R Bersell; Huan He; Jose R Pinto; Dmytro O Kryshtal; Bjorn C Knollmann
Journal:  J Mol Cell Cardiol       Date:  2017-12-05       Impact factor: 5.000

Review 4.  Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy.

Authors:  Sunil Yadav; Danuta Szczesna-Cordary
Journal:  Biophys Rev       Date:  2017-01-25

5.  Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.

Authors:  Marco L Alves; Fernando A L Dias; Robert D Gaffin; Jillian N Simon; Eric M Montminy; Brandon J Biesiadecki; Aaron C Hinken; Chad M Warren; Megan S Utter; Robert T Davis; Sadayappan Sakthivel; Jeffrey Robbins; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  Circ Cardiovasc Genet       Date:  2014-02-28

6.  Length-dependent activation is modulated by cardiac troponin I bisphosphorylation at Ser23 and Ser24 but not by Thr143 phosphorylation.

Authors:  Paul J M Wijnker; Vasco Sequeira; D Brian Foster; Yuejin Li; Cristobal G Dos Remedios; Anne M Murphy; Ger J M Stienen; Jolanda van der Velden
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-02-28       Impact factor: 4.733

Review 7.  Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations.

Authors:  Wenrui Huang; Danuta Szczesna-Cordary
Journal:  J Muscle Res Cell Motil       Date:  2015-09-18       Impact factor: 2.698

8.  The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy.

Authors:  Stephen W Luckey; Lori A Walker; Tyson Smyth; Jason Mansoori; Antke Messmer-Kratzsch; Anthony Rosenzweig; Eric N Olson; Leslie A Leinwand
Journal:  J Mol Cell Cardiol       Date:  2009-02-21       Impact factor: 5.000

9.  Phosphorylation of protein kinase C sites Ser42/44 decreases Ca(2+)-sensitivity and blunts enhanced length-dependent activation in response to protein kinase A in human cardiomyocytes.

Authors:  Paul J M Wijnker; Vasco Sequeira; E Rosalie Witjas-Paalberends; D Brian Foster; Cristobal G dos Remedios; Anne M Murphy; Ger J M Stienen; Jolanda van der Velden
Journal:  Arch Biochem Biophys       Date:  2014-05-09       Impact factor: 4.013

10.  Frequency-dependent myofilament Ca2+ desensitization in failing rat myocardium.

Authors:  Regis R Lamberts; Nazha Hamdani; Tenoedj W Soekhoe; Nicky M Boontje; Ruud Zaremba; Lori A Walker; Pieter P de Tombe; Jolanda van der Velden; Ger J M Stienen
Journal:  J Physiol       Date:  2007-05-03       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.